Skip to main content

Table 1 Percentage of resected NSCLC stage II and IIIA patients treated with practice guideline recommended adjuvant chemotherapy following surgery by Local Health Integration Network (LHIN) Region of Residence (patients diagnosed in 2009)

From: A mixed methods approach to understand variation in lung cancer practice and the role of guidelines

LHIN

Guideline treatment (RCC)

Treated non-RCC

Alternate treatment

No treatment <120 days of Surgery

Total resected II&IIIA cases

1

32%

6%

3%

59%

34

2

38%

4%

4%

53%

68

3

16%

19%

19%

47%

43

4

46%

2%

7%

46%

61

5

10%

41%

10%

38%

29

6

32%

27%

5%

35%

37

7

29%

32%

5%

34%

65

8

40%

25%

3%

32%

68

9

49%

11%

6%

34%

83

10

52%

4%

11%

33%

27

11

61%

1%

7%

31%

72

12

37%

24%

11%

28%

46

13

50%

4%

4%

42%

50

14

65%

0%

10%

25%

20

Ontario

41%

14%

7%

38%

703

  1. NSCLC, non-small cell lung cancer; RCC, Regional Cancer Centre.
  2. Report date: December, 2011.
  3. Data source: Cancer Care Ontario, ALR, OCR.
  4. Notes:
  5. Many patients in the “No Treatment” category may not be medically fit for the practice guideline treatment due to factors we are not currently able to adjust for. Patients may also decline treatment for personal reasons. Others may have been treated outside Ontario.
  6. Alternate Treatment: cases receiving a therapy different from that recommended in the practice guidelines. This may include non-platinum-based chemotherapy or radiation therapy only.
  7. Treated Non RCC: patients receiving chemotherapy outside of a cancer centre where the drug regimen is not reported to Cancer Care Ontario (CCO).
  8. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information. However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of the Canadian Institute for Health Information.